公开(公告)号：US20180200412A1

公开(公告)日：2018-07-19

申请号：US15874757

申请日：2018-01-18

Applicant: Medtronic MiniMed, Inc.

Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

IPC: A61L29/14 ,  A61K9/00 ,  A61K38/28 ,  A61K31/727 ,  A61L29/04 ,  A61M5/142 ,  A61M5/158 ,  A61M5/38

CPC classification number: A61L29/146 ,  A61K9/0019 ,  A61K31/727 ,  A61K38/28 ,  A61L29/049 ,  A61M5/142 ,  A61M5/14248 ,  A61M5/14276 ,  A61M5/158 ,  A61M5/38 ,  A61M39/10 ,  A61M39/162 ,  A61M2005/1586 ,  A61M2205/0272 ,  A61M2205/3334 ,  A61M2205/584 ,  A61M2205/7545 ,  A61M2207/00 ,  A61M2230/201

Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

公开(公告)号：US20150112302A1

公开(公告)日：2015-04-23

申请号：US14512788

申请日：2014-10-13

Applicant: Medtronic MiniMed, Inc.

Inventor： Sarnath Chattaraj ,  Kiem H. Dang ,  Hsi Chung Fusselman ,  Poonam S. Gulati ,  Lance P. Hoffman ,  Guangping Zhang

IPC: A61K31/727 ,  A61L29/16 ,  A61L29/08 ,  A61M5/142 ,  A61K38/28

Abstract: Methods and devices are provided for reducing a diabetic patient's foreign body immune response, including infusion site-loss and/or occlusion. Such foreign body responses are associated with the treatment of the diabetic patient where the treatment requires subcutaneous implantation of a foreign body, such as a cannula or catheter. In certain embodiments of the invention, a response-inhibiting agent is administered to a patient at the site of cannula/catheter insertion, thereby facilitating delivery of insulin to the diabetic patient and mitigating site-loss and/or occlusion over a period of time.

Abstract translation: 提供了用于减少糖尿病患者的异物免疫应答的方法和装置，包括输注部位损失和/或闭塞。 这种异物反应与治疗需要皮下植入异物如插管或导管的糖尿病患者的治疗相关联。 在本发明的某些实施方案中，在套管/导管插入部位向患者施用反应抑制剂，由此有助于将胰岛素递送至糖尿病患者并减轻一段时间的部位损失和/或闭塞。

公开(公告)号：US10517892B2

公开(公告)日：2019-12-31

申请号：US14512788

申请日：2014-10-13

Applicant: Medtronic MiniMed, Inc.

Inventor： Sarnath Chattaraj ,  Kiem H. Dang ,  Hsi Chung Fusselman ,  Poonam S. Gulati ,  Lance P. Hoffman ,  Guangping Zhang

IPC: A61K31/727 ,  A61M5/142 ,  A61K38/28 ,  A61L29/08 ,  A61L29/16 ,  A61M5/158 ,  A61M5/168

Abstract: Methods and devices are provided for reducing a diabetic patient's foreign body immune response, including infusion site-loss and/or occlusion. Such foreign body responses are associated with the treatment of the diabetic patient where the treatment requires subcutaneous implantation of a foreign body, such as a cannula or catheter. In certain embodiments of the invention, a response-inhibiting agent is administered to a patient at the site of cannula/catheter insertion, thereby facilitating delivery of insulin to the diabetic patient and mitigating site-loss and/or occlusion over a period of time.

公开(公告)号：US12208181B2

公开(公告)日：2025-01-28

申请号：US17823388

申请日：2022-08-30

Applicant: MEDTRONIC MINIMED, INC.

Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

IPC: A61L29/14 ,  A61K9/00 ,  A61K31/727 ,  A61K38/28 ,  A61L29/04 ,  A61M5/142 ,  A61M5/158 ,  A61M5/38 ,  A61M25/00 ,  A61M39/10 ,  A61M39/16

Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

公开(公告)号：US11197949B2

公开(公告)日：2021-12-14

申请号：US15874757

申请日：2018-01-18

Applicant: Medtronic MiniMed, Inc.

Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

IPC: A61L29/14 ,  A61K38/28 ,  A61K31/727 ,  A61L29/04 ,  A61M5/142 ,  A61M5/38 ,  A61K9/00 ,  A61M39/10 ,  A61M39/16 ,  A61M5/158

Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

公开(公告)号：US09199043B2

公开(公告)日：2015-12-01

申请号：US14041039

申请日：2013-09-30

Applicant: MEDTRONIC MINIMED, INC.

Inventor： Sarnath Chattaraj ,  Poonam S. Gulati ,  Lance P. Hoffman ,  Kiem Dang

IPC: A61M5/315 ,  A61M5/36

CPC classification number: A61M5/36 ,  A61M5/31511 ,  A61M5/31513 ,  Y10T29/49826

Abstract: A fluid syringe of the type used with fluid infusion devices is presented here. The fluid syringe generally includes a barrel, a piston, and a check valve seal. The barrel has an interior wall and a sealed main fluid chamber. The piston is slidably coupled within the barrel, and the piston has a piston seal forming an interference fluid seal against the interior wall. The check valve seal is coupled to the piston, and it is located between the piston seal and the main fluid chamber. The check valve seal forms an interference fluid seal against the interior wall when the piston is unloaded, and it disengages the interior wall to allow gas flow from the main fluid chamber toward the piston seal when the piston is loaded.

Abstract translation: 这里介绍了一种与流体输注装置一起使用的流体注射器。 流体注射器通常包括桶，活塞和止回阀密封。 桶具有内壁和密封的主流体室。 活塞可滑动地联接在筒内，并且活塞具有形成抵抗内壁的干涉流体密封的活塞密封件。 止回阀密封件联接到活塞，并且其位于活塞密封件和主流体室之间。 止回阀密封件在活塞卸载时形成抵靠内壁的干涉流体密封，并且当活塞被装载时，止回阀密封件脱离内壁以允许气体从主流体室流向活塞密封件。

公开(公告)号：US12201752B2

公开(公告)日：2025-01-21

申请号：US17499612

申请日：2021-10-12

Applicant: Medtronic MiniMed, Inc.

Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

IPC: A61L29/14 ,  A61K9/00 ,  A61K31/727 ,  A61K38/28 ,  A61L29/04 ,  A61M5/142 ,  A61M5/158 ,  A61M5/38 ,  A61M25/00 ,  A61M39/10 ,  A61M39/16

Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

公开(公告)号：US20220409777A1

公开(公告)日：2022-12-29

申请号：US17823388

申请日：2022-08-30

Applicant: MEDTRONIC MINIMED, INC.

Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

IPC: A61L29/14 ,  A61K38/28 ,  A61K31/727 ,  A61L29/04 ,  A61M5/142 ,  A61M5/38 ,  A61K9/00 ,  A61M39/10 ,  A61M39/16

Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

公开(公告)号：US20220031941A1

公开(公告)日：2022-02-03

申请号：US17499612

申请日：2021-10-12

Applicant: Medtronic MiniMed, Inc.

Inventor： Kiem H. Dang ,  Sarnath Chattaraj ,  Hsi C. Fusselman ,  Lance P. Hoffman ,  Guangping Zhang

IPC: A61M5/168 ,  A61M5/142 ,  A61M5/162

Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

公开(公告)号：US20140031749A1

公开(公告)日：2014-01-30

申请号：US14041039

申请日：2013-09-30

Applicant: MEDTRONIC MINIMED, INC.

Inventor： Sarnath Chattaraj ,  Poonam S. Gulati ,  Lance P. Hoffman ,  Kiem Dang

IPC: A61M5/36 ,  A61M5/315

CPC classification number: A61M5/36 ,  A61M5/31511 ,  A61M5/31513 ,  Y10T29/49826

Abstract: A fluid syringe of the type used with fluid infusion devices is presented here. The fluid syringe generally includes a barrel, a piston, and a check valve seal. The barrel has an interior wall and a sealed main fluid chamber. The piston is slidably coupled within the barrel, and the piston has a piston seal forming an interference fluid seal against the interior wall. The check valve seal is coupled to the piston, and it is located between the piston seal and the main fluid chamber. The check valve seal forms an interference fluid seal against the interior wall when the piston is unloaded, and it disengages the interior wall to allow gas flow from the main fluid chamber toward the piston seal when the piston is loaded.

Abstract translation: 这里介绍了一种与流体输注装置一起使用的流体注射器。 流体注射器通常包括桶，活塞和止回阀密封。 桶具有内壁和密封的主流体室。 活塞可滑动地联接在筒内，并且活塞具有形成抵抗内壁的干涉流体密封的活塞密封件。 止回阀密封件联接到活塞，并且其位于活塞密封件和主流体室之间。 止回阀密封件在活塞卸载时形成抵靠内壁的干扰流体密封，并且当活塞被装载时，止回阀密封件脱离内壁以允许气体从主流体室流向活塞密封件。